两种常用抗肝纤维化中成药临床疗效的比较

目的：比较扶正化瘀胶囊和安络化纤丸临床抗肝纤维化作用。方法选择99例肝纤维化患者，随机分为两组，分别采用扶正化瘀胶囊治疗51例和安络化纤丸治疗48例，疗程为12个月，观察两组治疗前后 Fibroscan 值、肝纤维化四项、肝脏彩色超声以及肝脏病理学等的变化。结果经治疗后，扶正化瘀胶囊组 Fibroscan 值为8．25 KPa、HA 为143．4 ng/mL、LN 为95．9 ng/mL、PC-III 为109．3 ng/mL、Ⅳ-C 为72．1 ng/mL、门静脉内径为10．13 mm、脾脏厚度为38．40 mm。安络化纤丸组 Fibroscan 值为13．04 kPa、HA 为208．7 ng/mL、LN 为155．5 ng/mL、PC-III 为110．0 ng/mL、Ⅳ-C 为117．5 ng/mL、门静脉内径为12．61 mm、脾脏厚度为45．01 mm。两组相比差异有统计学意义（P ＜0．05），此外扶正化瘀胶囊改善纤维化分级具有显著的效果（P ＜0．05）。结论与安络化纤丸相比，扶正化瘀胶囊具有更好的临床疗效。

Comparison of therapeutic efficacy between two Chinese patent drugs for liver fibrosis

Objective To compare the therapeutic efficacy between Fuzheng Huayu capsule and AnLuo HuaXian pill.Methods Ninety-nine patients with liver fibrosis were randomly divided into two groups.Group one received Fuzheng Huayu capsule treatment and group two received AnLuo HuaXian pill treatment.All patients received treatment for 12 months.Fibroscan value,liver fibrosis indexes,color ultrasound images and liver pathology were measured before and after treatment.Results After treatment,the Fibroscan value of Fuzheng Huayu capsule group was 8.25 KPa, liver fibrosis indexes were HA： 143.4 ng/mL、LN：95.9 ng/mL、PC-III： 109.3 ng/mL、Ⅳ-C：72.1 ng/mL, respectively.The inside diameter of portal vein was 10.13 mm and thickness of spleen was 38.40 mm.The Fibroscan value of AnLuo HuaXian pill group was 13.04 kPa,liver fibrosis indexes were HA：208.7 ng/mL、LN：155.5 ng/mL、PC-III：110.0 ng/mL、Ⅳ-C：117.5 ng/mL,respectively.The inside diameter of portal vein was 12.61 mm and thickness of spleen was 45.01 mm.There were significant differences in the indexes above between the two groups （P 〈0.05 ）, What is more,Fuzheng Huayu capsule showed a better effect on improving the fibrosis grades （P 〈0.05）.Conclusion Fuzheng Huayu capsule is more effective for liver fibrosis treatment than AnLuo HuaXian pill.